ロード中...
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
BACKGROUND: Gemcitabine plus nab-paclitaxel (GA) and modified FOLFIRINOX (FFX) have been widely used as standard first-line treatment in pancreatic cancer. However, it is unclear which regimen is more efficacious. AIM: To evaluate a retrospective analysis comparing the efficacy and safety of FFX and...
保存先:
| 出版年: | World J Clin Cases |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Baishideng Publishing Group Inc
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7479547/ https://ncbi.nlm.nih.gov/pubmed/32953848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v8.i17.3718 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|